Department of Chemistry, Hunter College, 695 Park Avenue, New York, NY 10065, USA.
Bioorg Med Chem. 2013 Nov 1;21(21):6554-64. doi: 10.1016/j.bmc.2013.08.027. Epub 2013 Aug 29.
The tetrahydrofuran (THF) containing annonaceous acetogenins (AAs) are attractive candidates for drug development because of their potent cytotoxicity against a wide range of tumors and their relatively simple and robust structures. Replacement of the THF segment with a sugar residue may deliver analogues with improved tumor selectivity and pharmacokinetics and are therefore attractive for drug development. As a first test to the feasibility of such structures, a set of such monosaccharide analogues was synthesized and assayed against four human tumor cell lines, cervical (HeLa), breast (MDA-MB231), T-cell leukemia (Jurkat) and prostate (PC-3). Certain analogues showed low micromolar activity that was comparable to a structurally similar, naturally occurring mono-THF acetogenin. A preliminary examination of the structure-activity profile of these carbohydrate analogues suggests that they have a similar mechanism of action as their THF congeners.
含有呋喃(THF)的番荔枝内酯(AAs)是药物开发的有吸引力的候选物,因为它们对广泛的肿瘤具有强大的细胞毒性,并且它们的结构相对简单和稳健。用糖残基取代 THF 片段可能会提供具有改善的肿瘤选择性和药代动力学的类似物,因此适合药物开发。作为对这种结构可行性的第一个测试,合成了一组这样的单糖类似物,并针对四种人类肿瘤细胞系(宫颈(HeLa),乳腺(MDA-MB231),T 细胞白血病(Jurkat)和前列腺(PC-3)进行了测定。某些类似物显示出低微摩尔的活性,与结构相似的天然单 THF 乙酰基生酮相当。对这些碳水化合物类似物的结构活性谱的初步检查表明,它们具有与 THF 同系物相似的作用机制。